STOCKHOLM, July 31st, 2019, Moberg Pharma AB (OMX: MOB). The number of shares and votes in Moberg Pharma AB (publ) ("Moberg Pharma") has increased by 488,905 ordinary shares in July 2019. Therefore, there are in total 18,853,510 shares and votes in the company as of July 31st 2019, of which 18,192,667 are ordinary shares and 660,843 are shares of series B.
The total number of shares and votes has increased as a result of 488,905 ordinary shares issued after exercise of warrants under Moberg Pharma's share-based incentive program. Due to the exercise of the warrants, the total number of shares and votes has increased by 488,905 from 18,364,605 to 18,853,510 and the share capital has increased by SEK 48,890.50 from SEK 1,836,460.50 to SEK 1,885,351.00.
At the time of this press release the Company holds 184,746 own ordinary shares.
About this information
This information is such that Moberg Pharma AB (publ) is obliged to disclose pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. (CET) on July 31st 2019.
For additional information, please contact:
Anna Ljung, CEO, telephone: +46 707 66 60 30, E-mail: email@example.com
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's main asset, MOB-015, is a novel topical treatment for onychomycosis, for which phase 3 data in 800+ patients is expected in late 2019 in North America and the first half of 2020 in Europe. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company's shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).
(c) 2019 Cision. All rights reserved., source Press Releases - English